<DOC>
	<DOCNO>NCT00690937</DOCNO>
	<brief_summary>A total 120 patient enter study ass safety efficacy enteric coat sevelamer ( ECS ) low LDL cholesterol . Patients randomize two active treatment group , two placebo group one active control group .</brief_summary>
	<brief_title>A Multicenter , Active Placebo-controlled Study Enteric Coated Sevelamer Patients With Mild Moderate Hypercholesteremia</brief_title>
	<detailed_description>This prospective , randomize , single blind , active placebo-controlled , parallel-group , multi-center study . Two group ECS consist 3 6 tablets/day ( n=30 ) , two placebo group 3 6 tablets/day ( n=15 ) one active control group colesevelam 6 tablets/day ( n=30 ) . The study conduct solely India total 6-8 site . The safety parameter : - Serious adverse event SAEs - Treatment non-treatment emergent AEs - Physical exam vital sign - Clinical safety laboratories The efficacy parameter include fast lipid profile : - Low density lipoprotein ( LDL ) - Total cholesterol - High density lipoprotein ( HDL ) - Triglycerides</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Males females 18 year age old Clinical diagnosis mild moderate hypercholesterolemia 1 ) LDL cholesterol great equal 130 mg/dL less equal 220 mg/dL 2 ) Triglycerides le equal 300 mg/dL Women pregnant lactating . Patients use lipidlowering medication . Patients unstable medical condition and/or comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>hypercholesterolemia , bile acid sequestrant , LDL-cholesterol</keyword>
</DOC>